MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• MBX Biosciences experienced a surge in trading volume with approximately 543,479 shares traded, marking a 10% increase from the previous session.
• The stock is currently down 1.5%, trading at $19.81 after closing at $20.00.
• Wall Street Zen upgraded MBX from a "sell" to a "hold" rating, indicating a more favorable outlook for the company's stock performance.

Shares of MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 543,479 shares changed hands during mid-day trading, an increase of 10% from the previous session's volume of 494,550 shares.The stock last traded at $19.81 and had previously closed at $20.00.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded MBX Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, September 13th.

MBX Biosciences Stock Down 1.5%

The company has a market cap of $661.72 million and a price-to-earnings ratio of -4.34.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.